Bristol-Myers Receives FDA Approval for Celgene’s Ozanimod
Bristol-Myers Squibb (BMY) (BMYMP) announced that it has received the FDA approval for Ozanimod, an MS drug it acquired through its purchase of Celgene business. The approval comes after quite a few roadblocks including an initial rejection by the FDA. The drug is scheduled to be marketed under the brand name of Zeposia and is aimed to treat relapsing MS. In its trials, the drug showed a relative reduction in ARR versus AVONEX of 48% through one year and 38% at two years.
Bristol-Myers Squibb did